FDA Clarifies Leucovorin's Role, Disappoints Autism Treatment Hopes

The FDA has updated the label for leucovorin, a medication previously suggested as a potential treatment for autism, clarifying its use is limited to a rare genetic condition affecting folate transport in the brain. This condition, which impacts about 1 in a million people, has been recognized in fewer than 50 cases globally. The FDA's recent approval is seen as a significant milestone for those with this specific deficiency, but officials have stated there is insufficient evidence to support leucovorin as a treatment for broader autism symptoms. This development follows a surge in prescriptions for leucovorin after a controversial White House briefing in September, leading to difficulties for families trying to access the medication. Parents are now facing challenges in obtaining prescriptions, with some turning to unregulated supplements as alternatives.

Key Details: • Leucovorin is now approved for a rare genetic condition, not autism. • The condition affects approximately 1 in a million people. • Parents reported difficulties in obtaining leucovorin prescriptions. • Some families are resorting to unregulated folate supplements.